Holen Sie sich die Stockscreener-App
27.93
9.35%
-2.88
Schlusskurs vom Vortag:
$30.81
Offen:
$32
24-Stunden-Volumen:
5.07M
Relative Volume:
1.40
Marktkapitalisierung:
$2.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-12.99
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
-15.49%
1M Leistung:
+43.75%
6M Leistung:
+581.22%
1J Leistung:
+382.38%
1-Tages-Spanne:
$27.06
$32.00
1-Wochen-Bereich:
$27.06
$36.26
52-Wochen-Spanne:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
27.93 | 2.47B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025 - ts2.tech
Is Olema Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Trade Report & Detailed Earnings Play Strategies - DonanımHaber
Will Olema Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - Улправда
Why Olema Pharmaceuticals Inc. stock is popular among millennialsAnalyst Downgrade & Reliable Price Breakout Signals - Улправда
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.5%Time to Sell? - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Inc Stock Analysis and ForecastMomentum Trading Signals & Fast Profit Trading Tips - earlytimes.in
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 12-Month HighTime to Buy? - MarketBeat
Olema Oncology’s Stock Surge: Analyze Now? - timothysykes.com
Olema Oncology (OLMA) Sees Positive Surge in Stock Price - GuruFocus
Olema Pharmaceuticals Stock Surges Amid Analyst Optimism - TipRanks
Research Analysts Offer Predictions for OLMA FY2025 Earnings - MarketBeat
Lifesci Capital Has Positive Outlook of OLMA FY2025 Earnings - MarketBeat
Birchview Capital LP Invests $571,000 in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $48.00 - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $60.00 - MarketBeat
OLMA Stock: Citigroup Raises Price Target to $60, Maintains Buy - GuruFocus
Olema Pharmaceuticals (OLMA): HC Wainwright & Co. Raises Price T - GuruFocus
Olema Oncology (OLMA) Price Target Raised by Citi Amid Positive Trial Data - GuruFocus
Olema Pharmaceuticals (OLMA): Reassessing Valuation After Roche’s Phase 3 SERD Success Boosts Palazestrant Expectations - Sahm
Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News - GuruFocus
OLMA: Goldman Sachs Raises Price Target to $38 on Maintained Buy Rating | OLMA Stock News - GuruFocus
The Goldman Sachs Group Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6% Following Analyst Upgrade - MarketBeat
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT - Finviz
HC Wainwright Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $45.00 - MarketBeat
Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright - Investing.com Canada
HighVista Strategies LLC Acquires 66,245 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus
Jefferies raises Olema Pharmaceuticals stock price target to $43 on SERD validation - Investing.com UK
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know - ts2.tech
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 1-Year HighHere's Why - MarketBeat
Olema Oncology (OLMA) Shares Surge Over 11% - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week high at $29.57 - Investing.com
Roche boosts Olema after additional late-stage trial data for breast cancer drug - Seeking Alpha
Diadema Partners LP Increases Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals joins SABCS25 to advance breast cancer therapies - Traders Union
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.7%Here's Why - MarketBeat
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025 - ts2.tech
XTX Topco Ltd Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA Shares Bought by Schroder Investment Management Group - MarketBeat
Affinity Asset Advisors LLC Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (OLMA) price target increased by 53.92% to 37.23 - MSN
Why Olema Pharmaceuticals Inc. stock is rated strong buyChart Signals & Capital Protection Trade Alerts - Newser
Why retail investors favor Olema Pharmaceuticals Inc. stockMarket Sentiment Review & Long-Term Growth Plans - Newser
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals seeks senior medical director to advance oncology care - Traders Union
Olema Pharmaceuticals (OLMA) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
Olema Pharmaceuticals (OLMA): Assessing Valuation Following $190 Million Equity Offering and Underwriter Changes - Sahm
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):